Answers are grounded in this paper and cite their sources.
Review evaluates lymphatic-targeted nanoparticle delivery for better outcomes in cancer metastasis and lymphoma, suggesting a novel intervention.
The lymphatic system is a major pathway for the metastatic spread of solid tumours and is the primary site of lymphoproliferative malignancies. Standard systemic chemotherapy is afflicted with huge first-pass metabolism by the liver, dose-limiting systemic toxicity, and poor drug concentrations in the lymph nodes, the same locations where early metastatic deposits and lymphoma cells are found. The targeting of lymphatic capillaries (i.e., discontinuous basement membrane) and the size-dependent uptake thresholds of lymphatic capillaries are exploited by nanoparticle-based drug delivery systems as a transformative approach to target the lymphatic vasculature and lymph nodes selectively. A thorough review of the fundamental principles of rational design applied in the case of lymphatic-targeted nanoparticles is done, including the aspects of particle size, charge on the surface of the particle, and surface chemistry, as well as the route of administration. We discuss the key nanoplatforms, such as liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and albumin-based carriers, in the context of lymph node metastasis therapy and lymphoma therapy. The pharmacokinetic benefits of bypassing the hepatic first-pass metabolism by subcutaneous, intradermal, and oral lymphatic absorption routes are elaborated. Moreover, we evaluate the active targeting strategies with the use of lymphatic endothelial cell receptors (LYVE-1, podoplanin, mannose receptors) and stimuli-responsive release mechanisms. Preclinical and emergent clinical evidence is synthesized as well as the remaining issues such as translational barriers, toxicology issues and future directions are discussed. This review highlights the fact that rationally-designed nanoparticles, when delivered through lymphatic-accessing routes, can provide a paradigm shift in precision lymphatic oncology with better therapeutic indices.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: